The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer
Open accessPublished version of a preprint
Abstract
Purpose: The monocarboxylate transporter 1 (MCT1) inhibitor, AZD3965, is undergoing phase I evaluation in the United Kingdom. AZD3965 is proposed, via lactate transport modulation, to kill tumor cells reliant on glycolysis. We investigated the therapeutic potential of AZD3965 in small cell lung cancer (SCLC) seeking rationale for clinical testing in this disease and putative predictive biomarkers for trial use. Experimental Design: AZD3965 sensitivity was determined for seven SCLC cell lines, in normoxia and hypoxia, and for a tumor xenograft model. Proof of mechanism was sought via changes in intracellular/tumor lactate. Expression of MCT1 and related transporter MCT4 was assessed by Western blot analysis. Drug resistance was investigated via MCT4 siRNAi and overexpression. The expression and clinical significance of MCT1 and MCT4 were explored in a tissue microarray (TMA) from 78 patients with SCLC. Results: AZD3965 sensitivity varied in vitro and was highest in hypoxia. Resistance in hypoxia was associated with increased MCT4 expression. In vivo, AZD3965 reduced tumor growth and increased intratumor lactate. In the TMA, high MCT1 expression was associated with worse prognosis (P = 0.014). MCT1 and hypoxia marker CA IX expression in the absence of MCT4 was observed in 21% of SCLC tumors. Conclusions: This study provides a rationale to test AZD3965 in patients with SCLC. Our results suggest that patients with tumors expressing MCT1 and lacking in MCT4 are most likely to respond. Clin Cancer Res; 20(4); 926–37. ©2013 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Suppression of lactate efflux by cancer cells using the small molecule inhibitor AZ3965, α‐cyano‐4‐hydroxycinnamate (CHC), has shown promising results in preclinical models of Burkitt lymphoma, breast cancer, gastric cancer, small cell lung cancer and glioblastoma [208, 209].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [208]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Otto Warburg's contributions to current concepts of cancer metabolism
Koppenol, W. H., Bounds, P. L., & Dang, C. V. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3038 · Cited by 3,427
Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,845
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Peifer, M., Fernández-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,397
The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation
Halestrap, A. P., & Price, N. T. (1999) · Biochemical Journal · doi:10.1042/0264-6021:3430281 · Cited by 1,348
Cited by
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
The Science and Translation of Lactate Shuttle Theory
Brooks, G. A. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.008 · Cited by 1,486
Tumour acidosis: from the passenger to the driver's seat
Corbet, C., & Feron, O. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.77 · Cited by 988
Lactate modulation of immune responses in inflammatory versus tumour microenvironments
Certo, M., Tsai, C.-H., Pucino, V., Ho, P.-C., & Mauro, C. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-0406-2 · Cited by 924
SLC Transporters as Therapeutic Targets: Emerging Opportunities
Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4626 · Cited by 835
Metadata
- Authors
- Polański, R., Hodgkinson, C. L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., Trapani, F., Bishop, P. W., White, A., Critchlow, S. E., Smith, P. D., Blackhall, F., Dive, C., & Morrow, C. J.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Dive, Caroline
- Morrow, Christopher J.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2014-02-15
- Volume
- 20
- Issue
- 4
- Pages
- 926-937
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC3929348
- OpenAlex
- W2020369202
- Cited by
- 378
- References
- 45
- Citations by year
- 2026: 39 · 2025: 39 · 2024: 34 · 2023: 33 · 2022: 31 · 2021: 28 · 2020: 41 · 2019: 34 · 2018: 22 · 2017: 24 · 2016: 24 · 2015: 19 · 2014: 10
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Funders
- Cancer Research UK (19278, A12328, C147/a12328)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- AZD3965, MCT1, MCT4, small cell lung cancer, lactate transport, tumor hypoxia, glycolysis, drug resistance, predictive biomarkers, CAIX, prognosis, tumor xenografts
- MeSH terms
- Monocarboxylate Transport Protein 1, Adult, Aged, Aged, 80 and over, Animals, Antineoplastic Agents, Female, Humans, Lung Neoplasms, Male, Middle Aged, Muscle Proteins, Pyrimidinones, Thiophenes, Multivariate Analysis, Mice, SCID, Mice, Inbred NOD, Cell Death, Drug Resistance, Neoplasm, Lactic Acid, Inhibitory Concentration 50, Xenograft Model Antitumor Assays, Monocarboxylic Acid Transporters, Symporters, Cell Line, Tumor, Mice, Kaplan-Meier Estimate, Small Cell Lung Carcinoma
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-13-2270
- The paper
- Polański, R., Hodgkinson, C. L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., Trapani, F., Bishop, P. W., White, A., Critchlow, S. E., Smith, P. D., Blackhall, F., Dive, C., & Morrow, C. J. (2014). Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-13-2270
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.